Eastman Kodak Company: Q2 1994 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 1994. Eastman Kodak Company is a global leader in imaging and related technologies. During this period, the Company announced a strategic refocus on consumer and commercial imaging businesses, resulting in the reclassification of its Health segment (Sterling Winthrop Inc. pharmaceutical and consumer health businesses) as discontinued operations. The Company is actively negotiating the divestiture of these health businesses, including an agreement to sell the pharmaceutical business to Sanofi for $1.675 billion.
Key Financial Metrics (in millions, except per share)
| Metric | Q2 1994 | Q2 1993 | YTD 1994 | YTD 1993 |
|---|---|---|---|---|
| Total Revenues | $3,469 | $3,407 | $6,248 | $6,150 |
| Net Earnings (Loss) | $264 | $371 | $346 | $(1,648) |
| EPS (Primary) | $0.79 | $1.13 | $1.04 | $(5.05) |
| Operating Cash Flow | N/A | N/A | $193 | $129 |
| Cash & Equivalents | $491 | N/A | $491 | N/A |
| Total Debt (Short + Long) | $6,341 | N/A | $6,341 | N/A |
| Working Capital | $1,023 | N/A | $1,023 | N/A |
Note: YTD 1993 Net Loss was driven by a $2.17 billion after-tax charge for the adoption of SFAS No. 106 and 112 regarding postretirement benefits.
Material Changes vs. Prior Period
- Revenue: Sales from continuing operations increased slightly (2% in Q2, 3% YTD) due to higher volumes, partially offset by lower effective selling prices and unfavorable currency effects.
- Profitability: Earnings from continuing operations before extraordinary items decreased 16% in Q2 ($295M vs $350M) and 12% YTD ($440M vs $498M). Margins were pressured by cost escalation and inventory valuation adjustments of approximately $30 million.
- Discontinued Operations: The Health segment reported a loss of $30 million in Q2 and $81 million YTD, primarily due to the allocation of interest expense ($114M in Q2) related to the pending divestiture.
- Liquidity: Cash and marketable securities declined significantly from $1.966 billion at year-end 1993 to $625 million at June 30, 1994. This reduction was used to redeem debt and terminate a Master Lease agreement.
- Debt: Total borrowings decreased by $997 million from year-end 1993 levels.
Outlook, Risks, and Unusual Items
- Divestitures: The Company expects to complete the sale of the Sterling Winthrop pharmaceutical business to Sanofi upon regulatory approval. Proceeds are planned to reduce debt, which may trigger material extraordinary charges for early extinguishment of debt.
- Segment Restructuring: Effective Q2 1994, the Company reorganized into Consumer Imaging and Commercial Imaging segments. The Health segment is now reported as discontinued.
- Acquisition: On August 12, 1994, Kodak purchased the remaining 50% interest in Qualex Inc. for $150 million, consolidating it into the third quarter.
- Legal & Environmental: The Company faces an EPA investigation regarding the Kodak Park site, expecting a civil fine of at least $100,000. It is also a potentially responsible party at fewer than twenty Superfund sites, though costs are not expected to be material.
- Guidance: Management expects positive operating cash flow for the full year 1994.
Investor Verification Checklist
- Divestiture Closing: Verify the status of regulatory approvals for the Sanofi acquisition of Sterling Winthrop's pharmaceutical business.
- Debt Extinguishment Charges: Monitor for potential extraordinary charges related to the early repayment of debt using divestiture proceeds.
- Health Segment Sales: Confirm the closing dates for the remaining non-imaging health businesses (L&F Products, Clinical Diagnostics) currently in negotiation.
- Qualex Integration: Review Q3 1994 results for the impact of consolidating Qualex Inc. operations.
- Environmental Liabilities: Track the outcome of the EPA/NEIC investigation at the Rochester site and any updates on Superfund site cost allocations.